A functional mTORC1 signaling is indispensable for c-Myc driven hepatocarcinogenesis
暂无分享,去创建一个
Ligong Chen | Xin Chen | A. Cossu | J. Tao | S. Ribback | F. Dombrowski | G. Vidili | Giuseppe | Lili Cheng | G. Pes | Kun Sun | A. Cigliano | Junjie Hu | M. Sini | F. Diego | S. Brozzetti | A. Porcu | M. G. Pilo | R. Pascale | Palmieri | Pingyi Liu | L. Che | Calvisi | Xiaolei Li | Yuedong Huang | Mengmeng Ge | M. Pilo | Maria G. Pilo
[1] D. Calvisi,et al. Activated mutant forms of PIK3CA cooperate with RasV12 or c‐Met to induce liver tumour formation in mice via AKT2/mTORC1 cascade , 2016, Liver international : official journal of the International Association for the Study of the Liver.
[2] G. Evan,et al. Identification of MYC-Dependent Transcriptional Programs in Oncogene-Addicted Liver Tumors. , 2016, Cancer research.
[3] R. Loewith,et al. TORC2 Structure and Function. , 2016, Trends in biochemical sciences.
[4] Ahmedin Jemal,et al. Annual Report to the Nation on the Status of Cancer, 1975‐2012, featuring the increasing incidence of liver cancer , 2016, Cancer.
[5] K. Evason,et al. Monocytes promote liver carcinogenesis in an oncogene-specific manner. , 2016, Journal of hepatology.
[6] S. Pascual,et al. New advances in hepatocellular carcinoma. , 2016, World journal of hepatology.
[7] D. Calvisi,et al. Co-activation of AKT and c-Met triggers rapid hepatocellular carcinoma development via the mTORC1/FASN pathway in mice , 2016, Scientific Reports.
[8] W. Ritchie,et al. ASCT2/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer , 2015, Oncogene.
[9] P. Massion,et al. Targeting SLC1a5‐mediated glutamine dependence in non‐small cell lung cancer , 2015, International journal of cancer.
[10] J. Zucman‐Rossi,et al. Genetic Landscape and Biomarkers of Hepatocellular Carcinoma. , 2015, Gastroenterology.
[11] J. Llovet,et al. Advances in targeted therapies for hepatocellular carcinoma in the genomic era , 2015, Nature Reviews Clinical Oncology.
[12] K. Giacomini,et al. SLC transporters as therapeutic targets: emerging opportunities , 2015, Nature Reviews Drug Discovery.
[13] Y. Bhutia,et al. Amino Acid transporters in cancer and their relevance to "glutamine addiction": novel targets for the design of a new class of anticancer drugs. , 2015, Cancer research.
[14] C. Mathers,et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.
[15] Jeffrey W. Smith,et al. 4EBP1/eIF4E and p70S6K/RPS6 axes play critical and distinct roles in hepatocarcinogenesis driven by AKT and N‐Ras proto‐oncogenes in mice , 2015, Hepatology.
[16] Z. Lou,et al. The Long Non-Coding RNA GAS5 Cooperates with the Eukaryotic Translation Initiation Factor 4E to Regulate c-Myc Translation , 2014, PloS one.
[17] M. Kudo,et al. Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial. , 2014, JAMA.
[18] D. Sabatini,et al. Regulation of mTORC1 by amino acids. , 2014, Trends in cell biology.
[19] D. Felsher,et al. MYC activation is a hallmark of cancer initiation and maintenance. , 2014, Cold Spring Harbor perspectives in medicine.
[20] S. Thorgeirsson,et al. Targeting the mTOR pathway in hepatocellular carcinoma: current state and future trends. , 2014, Journal of hepatology.
[21] D. Calvisi,et al. Hydrodynamic transfection for generation of novel mouse models for liver cancer research. , 2014, The American journal of pathology.
[22] M. Gleave,et al. Targeting amino acid transport in metastatic castration-resistant prostate cancer: effects on cell cycle, cell growth, and tumor development. , 2013, Journal of the National Cancer Institute.
[23] Dudley Lamming,et al. A Central role for mTOR in lipid homeostasis. , 2013, Cell metabolism.
[24] K. Shokat,et al. Myc and mTOR converge on a common node in protein synthesis control that confers synthetic lethality in Myc-driven cancers , 2013, Proceedings of the National Academy of Sciences.
[25] M. Manns,et al. Activity of the mTOR inhibitor RAD001, the dual mTOR and PI3‐kinase inhibitor BEZ235 and the PI3‐kinase inhibitor BKM120 in hepatocellular carcinoma , 2013, Liver international : official journal of the International Association for the Study of the Liver.
[26] A. Edinger,et al. Nutrient transporters: the Achilles’ heel of anabolism , 2013, Trends in Endocrinology & Metabolism.
[27] K. Guan,et al. Amino acid signalling upstream of mTOR , 2013, Nature Reviews Molecular Cell Biology.
[28] Edward Kai-Hua Chow,et al. Oncogene‐specific formation of chemoresistant murine hepatic cancer stem cells , 2012, Hepatology.
[29] D. Sabatini,et al. mTOR Signaling in Growth Control and Disease , 2012, Cell.
[30] Chi V Dang,et al. MYC on the Path to Cancer , 2012, Cell.
[31] S. Gambhir,et al. MYC phosphorylation, activation, and tumorigenic potential in hepatocellular carcinoma are regulated by HMG-CoA reductase. , 2011, Cancer research.
[32] D. Calvisi,et al. Increased lipogenesis, induced by AKT-mTORC1-RPS6 signaling, promotes development of human hepatocellular carcinoma. , 2011, Gastroenterology.
[33] D. Sabatini,et al. mTOR: from growth signal integration to cancer, diabetes and ageing , 2010, Nature Reviews Molecular Cell Biology.
[34] K. Shokat,et al. Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E. , 2010, Cancer cell.
[35] E. Schmidt,et al. Growth controls connect: Interactions between c-myc and the tuberous sclerosis complex-mTOR pathway , 2009, Cell cycle.
[36] D. Sabatini,et al. An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1* , 2009, Journal of Biological Chemistry.
[37] S. Paggi,et al. Sorafenib in Advanced Hepatocellular Carcinoma , 2008 .
[38] Derek Y. Chiang,et al. Pivotal role of mTOR signaling in hepatocellular carcinoma. , 2008, Gastroenterology.
[39] Sang Gyun Kim,et al. Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation , 2008, Proceedings of the National Academy of Sciences.
[40] R. Cencic,et al. c-Myc and eIF4F are components of a feedforward loop that links transcription and translation. , 2008, Cancer research.
[41] F. Lang,et al. The serine/threonine kinases SGK1, 3 and PKB stimulate the amino acid transporter ASCT2. , 2005, Biochemical and biophysical research communications.
[42] Christopher H. Contag,et al. MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer , 2004, Nature.
[43] T. Gansler,et al. c-myc amplification in hepatocellular carcinoma predicts unfavorable prognosis. , 1996, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.
[44] H. Hsu,et al. Amplification of the c-myc gene in human hepatocellular carcinoma: biologic significance. , 1993, Journal of the Formosan Medical Association = Taiwan yi zhi.
[45] W. Tansey,et al. Proteolytic control of the oncoprotein transcription factor Myc. , 2011, Advances in cancer research.